Ethical issues in placebo-controlled trials in Alzheimer's disease
Correspondence:
- 1.
- Haegerstam G, Huitfeldt B, Nilsson BS, et al. Placebo in clinical drug trials -- a multidisciplinary review. Methods Find Exp Clin Pharmacol 1982; 4: 261-278.
- 2.
- Klerman GL. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull 1986; 22: 25-29.
- 3.
- National Health and Medical Research Council. National statement on ethical conduct in research involving humans. Canberra: NHMRC, 1999.
- 4.
- Brodaty H, Sachdev P. Drugs for the prevention and treatment of Alzheimer's disease. Med J Aust 1997; 167: 447-452.
- 5.
- Knapp MJ, Knopman DS, Solomon PH, et al. A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
- 6.
- Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
- 7.
- National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999.
- 8.
- Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. Psychiatr Res 1998; 32: 151-159.
- 9.
- Keshavan MS, Haas GL, Kahn CE, et al. Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible? Psychiatr Res 1998; 32: 161-167.
- 10.
- Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577.
- 11.
- Emilien G, Beyreuther K, Masters CL, Maloteaux JM. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 2000; 57: 454-459.
- 12.
- Mariani L, Ventresca GP. Is the placebo still ethically acceptable and scientifically useful in clinical drug experimentation? Clin Ther 1996; 147: 595-598.
- 13.
- Whitehouse PJ. Future prospects for Alzheimer's disease therapy: ethical and policy issues for the international community. Acta Neurol Scand Suppl 1996; 165: 145-149.
- 14.
- Knopman D, Kahn J, Miles S. Clinical research designs for emerging treatments for Alzheimer disease: moving beyond placebo-controlled trials. Arch Neurol 1998; 55: 1425-1429.
- 15.
- Karlawish JH, Whitehouse PJ. Is the placebo control obsolete in a world after donepezil and vitamin E? Arch Neurol 1998; 55: 1420-1424.
- 16.
- Fry ST. Ethical issues in Alzheimer disease research. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 1): S54-S58.
- 17.
- Kawas CH, Clark CM, Farlow MR, et al. Clinical trials in Alzheimer disease: debate on the use of placebo controls. Alzheimer Dis Assoc Disord 1999; 13: 124-129.
- 18.
- Whitehouse PJ, Arizaga R, Brodaty H, et al. Placebos in clinical trials in Alzheimer disease: an international discussion. Alzheimer Dis Assoc Disord 1999; 13: 121-123.
Online responses are no longer available. Please refer to our instructions for authors page for more information.